LuckinJZ Posted - 54 minutes from now

$CADL today should be the reversing tide, don’t missed the wave

thedatasay20 Posted - 52 minutes from now

$CADL squeeze to $4.25 lets see it form a handle then break up to $4.65 next week. Lets go bulls!

thedatasay20 Posted - 36 minutes from now

@The1albatross good call on $CADL how much is your scale?

thedatasay20 Posted - 27 minutes from now

$CADL small gains here would be great, showing some momentum into December and signaling a bottom from recent down trend. In my opinion this needs to get above $5 before month end signaling reversal and beging of wave 5.

Yeettrader Posted - 5 minutes from now

$CADL 📈👀

The1albatross Posted - 21 seconds ago

$CADL Scaling for financial reasons. 3.8-4 floor before uptrend. Mega Cat here

paladinten17 Posted - 1 minute ago

$CADL / are we going to light this candle?

Xanderzzzzzzz Posted - 21 minutes ago

$CADL

thedatasay20 Posted - 25 minutes ago

$CADL ok this ticker needs to rally into read out! Lets go!

LuckinJZ Posted - 1 hour ago

$CADL picked up my last 5k shares

ak123456790 Posted - 1 hour ago

$CADL Also 25th of this month the CEO , will give updates for pancreas and lung trials

jagstox Posted - 1 hour ago

$CADL Its the MM Vermin that keep putting lower Bids and pushing the price down, maybe in cahoots with some Hedge Funds who may be buying it on the cheap...Unless we see some spine from Corporate Leadership to Defend the price and buy here, we'll be in this purgatory till we get amazing Results and a Partnership...

CarlAsf Posted - 1 hour ago

$CADL Price Target as Phase 3 readout is $60/share

ilikemoney247 Posted - 2 hours ago

$CADL great pipeline but they stated cash runway into Q1 2025 so i think offering early in the new year. might wait to further build my position after, i still got a good chunk at the moment

moneyrack Posted - 2 hours ago

$CADL I think the real hype would be if we meet primary endpoint for phase 2B prostate , basically ensuring cancer free with early intervention . I think Phase 3 endpoint is easier to meet as compared to 2B .

ak123456790 Posted - 2 hours ago

$CADL Small-Risk, High-Reward Play If phase 3 is Positive: i) CADL has the potential to transform the treatment landscape for localized prostate cancer, a huge market with unmet needs. ii) A partnership with big pharma could drive the stock to $30+ by 2025 and a $3,000 investment today ($4/share) could grow to ~$25,000. iii) A successful Phase 3 wouldn’t just boost CADL’s stock—it would elevate the company’s prestige, making big pharma more interested in its other programs (e.g., pancreatic, glioma lung cancer), increasing the odds of major partnerships or deals. If Data is Negative: i)Short-term drop (~$2), but CADL's pipeline (pancreatic, lung, glioma) still holds significant value. ii)Likely acquisition by big pharma could salvage or even boost long-term value. The risk-reward here is compelling: downside is limited by the pipeline, and the upside could be transformative. What do you think?

ElephantD Posted - 3 hours ago

$CADL there's no competition in the early localized pancreatic cancer. No new drug has been approved for over 20 years. Candel is the only company in phase 3 (it took 12 years to complete). If there's even the slightest benefit, the fda will approve it to get a new treatment out for that group. Ceo himself said extensive market analysis shows billion dollar opportunity. It will get bought out just because there is no competiton for the next 10 years. Big pharma wants easy billion dollar revenue with minimal cost (easy to manufacture). 4~8 billion dollar buyout is coming. Lily, Mercks, Jan, all have the cash

deporte1800 Posted - 3 hours ago

$CADL Don't ask me why? But every time Dr. Tak speaks or writes something I get more confident. And for some reason I get the impression that it could be a partnership or a buyout. My thinking is 50/50 right now. IMO. They have data even if it's not definitive, but I'm increasingly sure that the data is spectacular.

ak123456790 Posted - 3 hours ago

$CADL Why people are worried so much about the BLA time? If the phase 3 is successful, and then CEO partners with a big pharma such as GSK, then wouldn't take lesser than 2 years to be in the market? As the CEO said, he will partner with big pharma because he wants to give the drug to as many people as possible. Partnering with Europe and Asia could: i)Enable faster regulatory approval and commercialization in those regions. ii)Allow for staggered market entries, where CAN-2409 reaches Europe and Asia earlier than the U.S. (potentially late 2025 or early 2026) iii) Allow the CEO to secure upfront payments, milestone payments, and potential royalties from these deals. This fresh capital could then be reinvested into the U.S. manufacturing readiness and regulatory process for CAN-2409.

Tumble51 Posted - 4 hours ago

$CADL does a pair of aces, lol, beat a royal straight flush???? If not, it is just another biotech , low on cash, needs a partner , hasn’t got one stepping up, Tak somewhat impressive but no David Meeker for he holds a FULL HOUSE , A’s HIGH ..

Xanderzzzzzzz Posted - 4 hours ago

$CADL

drizz Posted - 5 hours ago

$CADL just listened to the Jeffries presentation - tak and the work being completed here is impressive imo - let’s hope tak is sitting on a pair of aces - we will know shortly but a very favorable risk reward here imo 🍀🍀🍀

BaridBanger Posted - 8 hours ago

$CADL

deporte1800 Posted - 8 hours ago

$CADL What is the other possibility that exists if the data is good? Withholding clinical trial results during ongoing partnership or acquisition negotiations can be beneficial or detrimental depending on the specific circumstances. Advantages of withholding data Maximizing negotiation leverage: Keeping the results private can prevent the partner company from using public knowledge of the data to push for more favorable terms. Confidentiality can increase the sponsor's leverage in negotiations. Alignment of interests: If the trial results are exceptionally positive, the negotiating partner may offer better terms, including higher upfront payments, royalties, or milestone bonuses, based on their confidence in the value of the asset. Avoiding market volatility: Public disclosure of results could lead to significant fluctuations in the stock price, which could complicate or undervalue the company's position during discussions. contunue...

deporte1800 Posted - 8 hours ago

$CADL We all know that Candel is cash poor. IMO. If the data is what the CEO and shareholders expect, Candel should already have an agreement in principle with a major pharmaceutical company to complete all the steps to bring the drug to market as soon as possible. Therefore, the announcement of an agreement should be imminent after the presentation of the results of the prostate trials. Although there is another possibility. What I am not clear about is whether this agreement will be a partnership or a BO. The CEO has always talked about a partnership but it could also be a way to play hard to get interested parties to put more money on the table in a BO. Who knows?

Xanderzzzzzzz Posted - 12 hours ago

$CADL

CarlAsf Posted - 12 hours ago

$CADL Price Target year end: $60/share

Xanderzzzzzzz Posted - 12 hours ago

$CADL Ph2b Active surveillance Primary end point--> Progression Free Survival

Xanderzzzzzzz Posted - 12 hours ago

$CADL Primary end point in Ph3 Intermediate/high risk prostate cancer----> Disease Free Survival

Xanderzzzzzzz Posted - 13 hours ago

$CADL PPT said this 5 months ago--> " We will not just sign a partnership because we are desperate-because we are not desperate. And we will find a way forward" ---------------------------- We have waited this long, few more days to go. We will find out. If they were desperate and didn't trust in the upcoming data readouts, they could have raised when SP was > $10 to $14. But they didn't do that. Why? Think. I am staying positive, long and strong.